HIGH TECH PHARM CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,560 KRW | -.--% |
|
+3.33% | +13.18% |
| Sales 2022 | 103B 74.33M 6.2B | Sales 2023 | 76.77B 55.43M 4.62B | Capitalization | 99.21B 71.63M 5.97B |
|---|---|---|---|---|---|
| Net income 2022 | 5.87B 4.24M 354M | Net income 2023 | 8.08B 5.83M 486M | EV / Sales 2022 | 0.83 x |
| Net Debt 2022 | 8.54B 6.17M 514M | Net Debt 2023 | 11.13B 8.04M 670M | EV / Sales 2023 | 1.44 x |
| P/E ratio 2022 |
13.2
x | P/E ratio 2023 |
12.3
x | Employees | 65 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 54.85% |
More Fundamentals
* Assessed data
More news
| 1 week | +3.33% | ||
| Current month | +4.14% | ||
| 1 month | +4.14% | ||
| 3 months | +21.10% | ||
| 6 months | +12.34% | ||
| Current year | +13.18% |
1 week
10 090.00
10 980.00
1 month
9 240.0010 980.00
Current year
7 880.0010 980.00
1 year
7 880.0011 186.67
3 years
5 740.0015 900.00
5 years
4 406.6719 633.33
10 years
4 406.6719 633.33
| Managers | Title | Age | Since |
|---|---|---|---|
Jeong-Soo Kim
CEO | Chief Executive Officer | 65 | - |
In-Cheol Kim
BRD | Director/Board Member | 56 | 25/16/25 |
Young-Hoon Kim
BRD | Director/Board Member | 59 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jeong-Soo Kim
CEO | Chief Executive Officer | 65 | - |
Young-Hoon Kim
BRD | Director/Board Member | 59 | - |
In-Cheol Kim
BRD | Director/Board Member | 56 | 25/16/25 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 10,560 | -.--% | 14,131 |
| 29/24/29 | 10,560 | -0.09% | 25,129 |
| 26/24/26 | 10,570 | -1.67% | 23,058 |
| 25/24/25 | 10,750 | -0.92% | 26,769 |
| 24/24/24 | 10,850 | +2.65% | 64,623 |
End-of-day quote Korea S.E., April 30, 2024
More quotes
HIGH TECH PHARM. CO., LTD. is a Korea-based company mainly engaged in the manufacture of antibiotic pharmaceutical ingredients for injections. The Company's products include sterile imipenem, sterile cilastatin sodium, sterile blended imipenem and cilastatin sodium, injectable sterile meropenem, injectable sterile panipenem, faropenem and others. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +13.18% | 81.13M | |
| +19.27% | 43.18B | |
| +24.05% | 23.23B | |
| +15.11% | 14.6B | |
| +12.33% | 13.54B | |
| +38.36% | 11.5B | |
| -7.63% | 6.79B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +10.21% | 5.31B |
- Stock Market
- Equities
- A106190 Stock
